The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal ...

Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed ...